FDA Approves First New Sunscreen Ingredient in Over 20 Years
FDA approves first new sunscreen ingredient – On Tuesday, the Food and Drug Administration (FDA) announced the inclusion of bemotrizinol as a new active ingredient in sunscreen products, marking the first such update since the late 1990s. This decision opens the door for manufacturers to incorporate the compound into their formulations, potentially enhancing sun protection for consumers. The approval follows a thorough evaluation of bemotrizinol’s safety and effectiveness, with the FDA emphasizing its role in advancing the sunscreen industry.
Key Features and Safety Profile
Bemotrizinol, a chemical compound developed by DSM Nutritional Products, offers broad-spectrum defense against both ultraviolet A (UVA) and ultraviolet B (UVB) radiation. According to the FDA, the ingredient demonstrates minimal absorption through the skin into the bloodstream, which reduces the risk of systemic side effects. This characteristic makes it a promising addition to the market, as it balances protective benefits with safety for all age groups.
“Bemotrizinol has been used safely in Europe for decades, and FDA’s action will increase competition and consumer confidence in sunscreen products,” stated Health and Human Services Secretary Robert F. Kennedy Jr. in a press release.
Kennedy highlighted that the approval aligns with the agency’s commitment to fostering innovation in the sunscreen sector. The Secretary also noted that this move reflects the FDA’s broader efforts to modernize regulatory processes and ensure that over-the-counter products meet current standards of quality and safety.
Regulatory Context and Industry Support
The decision to approve bemotrizinol comes in response to a September report from the Trump administration’s Make America Health Again Commission, which included Kennedy, Agriculture Secretary Brooke Rollins, and Education Secretary Linda McMahon. The 20-page report urged the FDA to streamline its approval procedures for sunscreen ingredients, arguing that the current system has lagged behind international standards. It called for measures to promote innovation and improve accessibility for consumers.
DSM Nutritional Products, a subsidiary of the Dutch multinational corporation DSM, submitted a formal request to the FDA for the inclusion of bemotrizinol in the over-the-counter sunscreen monograph last year. The company proposed using the ingredient at concentrations up to 6 percent, which the FDA reviewed extensively before reaching its conclusion. The agency’s proposal, released in December, concluded that studies provided sufficient evidence to confirm the ingredient’s safety under repeated exposure conditions.
The FDA’s final order, set to take effect on Wednesday, reaffirms that “there is adequate evidence from two independent human clinical efficacy studies” to support the effectiveness of bemotrizinol as a sunscreen active ingredient. These studies, which were conducted by third-party researchers, demonstrated the compound’s ability to block harmful UV rays without triggering adverse reactions such as irritation or photo-toxicity.
Implications for the Market and Consumers
Dr. Mike Davis, the acting director of the FDA Center for Drug Evaluation and Research, expressed his support for the approval in a statement. “The agency is committed to ensuring the American consumer has access to the most effective and safe therapies, including over-the-counter products like sunscreens,” he said. This endorsement underscores the FDA’s dedication to keeping up with scientific advancements and meeting evolving public health needs.
The addition of bemotrizinol is expected to stimulate competition among sunscreen manufacturers. DSM will exclusively sell the ingredient under the brand name Parsol Shield in the U.S. for 18 months following the final order’s implementation on August 9. During this period, other companies will not be able to market the compound, allowing DSM to capitalize on its early entry into the market. After this exclusivity phase, the ingredient will become available to a wider range of producers, potentially leading to more diverse product options for consumers.
Consumers are advised to apply sunscreen 15 minutes before sun exposure to allow the product to bind effectively to the skin. The FDA recommends covering all exposed areas, including the face and body, while avoiding the eyes and mouth. Reapplication should occur every two hours, or more frequently if individuals engage in activities like swimming or sweating. These guidelines are designed to maximize the protective benefits of sunscreen, particularly with the inclusion of new ingredients like bemotrizinol.
Industry experts have welcomed the approval, calling it a significant step forward for the sunscreen market. The lack of new active ingredients since the 1990s has limited product development, but bemotrizinol’s approval introduces fresh possibilities for enhancing UV protection. Its approval also reflects the FDA’s growing focus on aligning regulations with global standards, ensuring that U.S. consumers have access to cutting-edge skincare solutions.
As the sun protection landscape evolves, bemotrizinol’s inclusion into the FDA-approved list may prompt further research into its long-term effects and potential for use in specialized formulations. The decision not only benefits current users but also sets a precedent for future innovations in the field. With the ingredient now available, the FDA’s proactive approach to updating its standards continues to demonstrate its responsiveness to scientific progress and consumer demand.
